Stock Research for PRAN

PRAN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

PRAN Stock Chart & Research Data

The PRAN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PRAN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


PRAN Due diligence Resources & Stock Charts

The PRAN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PRAN Detailed Price Forecast - CNN Money CNN View PRAN Detailed Summary - Google Finance
Yahoo View PRAN Detailed Summary - Yahoo! Finance Zacks View PRAN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View PRAN Trends & Analysis - Trade-Ideas Barrons View PRAN Major Holders - Barrons
NASDAQ View PRAN Call Transcripts - NASDAQ Seeking View PRAN Breaking News & Analysis - Seeking Alpha
Spotlight View PRAN Annual Report - CompanySpotlight.com OTC Report View PRAN OTC Short Report - OTCShortReport.com
TradeKing View PRAN Fundamentals - TradeKing Charts View PRAN SEC Filings - Bar Chart
WSJ View Historical Prices for PRAN - The WSJ Morningstar View Performance/Total Return for PRAN - Morningstar
MarketWatch View the Analyst Estimates for PRAN - MarketWatch CNBC View the Earnings History for PRAN - CNBC
StockMarketWatch View the PRAN Earnings - StockMarketWatch MacroAxis View PRAN Buy or Sell Recommendations - MacroAxis
Bullish View the PRAN Bullish Patterns - American Bulls Short Pains View PRAN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View PRAN Stock Mentions - StockTwits PennyStocks View PRAN Stock Mentions - PennyStockTweets
Twitter View PRAN Stock Mentions - Twitter Invest Hub View PRAN Investment Forum News - Investor Hub
Yahoo View PRAN Stock Mentions - Yahoo! Message Board Seeking Alpha View PRAN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for PRAN - SECform4.com Insider Cow View Insider Transactions for PRAN - Insider Cow
CNBC View PRAN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PRAN - OTC Markets
Yahoo View Insider Transactions for PRAN - Yahoo! Finance NASDAQ View Institutional Holdings for PRAN - NASDAQ


Stock Charts

FinViz View PRAN Stock Insight & Charts - FinViz.com StockCharts View PRAN Investment Charts - StockCharts.com
BarChart View PRAN Stock Overview & Charts - BarChart Trading View View PRAN User Generated Charts - Trading View




Latest Financial News for PRAN


How Financially Strong Is Prana Biotechnology Limited (ASX:PBT)?
Posted on Thursday October 11, 2018

Prana Biotechnology Limited (ASX:PBT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PBT


Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA
Posted on Thursday October 04, 2018

Prana Biotechnology Ltd (PBT.AX) (PRAN) today announced further pre-clinical evidence for PBT434 will be presented in a poster at the International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong on Sunday, October 7th, 2018 at 1:45pm.


PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders
Posted on Sunday July 08, 2018

Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today announced it will be presenting further pre-clinical evidence for PBT434 at the International Congress of Parkinson’s Disease and Movement Disorders® to be held in Hong Kong from October 5-9, 2018. The data to be presented will include new in-vivo evidence of the efficacy of PBT434 to prevent neuron loss and improve function in an animal model of Multiple system atrophy (MSA), an important cause of atypical Parkinsonism. MSA is a rapidly progressive and devastating neurological disease with no established treatments and is one of the target indications for PBT434.


First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases
Posted on Tuesday July 03, 2018

Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases. The trial conducted in Melbourne, Australia is recruiting and dosing healthy adult and elderly volunteers, to ascertain the optimal drug dose.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.